Is the price fair?
What IRTC's price assumes
iRhythm Holdings, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 4.87× revenue.
4.87
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 1.1%
Free cash flow yield · Medical Devices median 4.0%
- Growth the price implies
- +26%
Growth the price implies · The price pays for +26% free cash flow growth a year for a decade; revenue has grown +22% a year over the last three.
- Price / book
- 23.8
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 23.8
- EV / EBIToperating margin −3.0%: the multiple describes the denominator
- not meaningful
- Free cash flow, trailing twelve months
- $39M
- Market capitalisation
- $3.44B
- 3-year revenue growth
- +22%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.